Celltrion says its tocilizumab biosimilar, Avtozma, is now commercially available to patients in the United States in subcutaneous formulation. Avtozma (tocilizumab-anoh) is one of the first FDA-approved tocilizumab biosimilars in both subcutaneous (SC) and intravenous (IV) forms. Approvals for both formulations first came in January 2025. Subcutaneous Formulation Follows Intravenous The SC form of Avtozma covers several indications. These include rheumatoid arthritis (RA), giant cell a...